Topical nepafenac in the treatment of center involving diabetic macular edema

• Main Author: T P Vignesh
• Format: Article
• Language: English
• Published: Wolters Kluwer Medknow Publications 2019-01-01
• Series: TNOA Journal of Ophthalmic Science and Research
• Subjects: center-involving diabetic macular edema; foveal thickness; nepafenac; prostaglandins
• Online Access: http://www.tnoajosr.com/article.asp?issn=2589-4528;year=2019;volume=57;issue=2;spage=109;epage=112;aulast=Vignesh

Purpose: To assess the efficacy of topical nepafenac 0.1% in the treatment of center-involving diabetic macular edema (DME). Design: A prospective, interventional case series. Methods: Fourteen eyes of thirteen patients with center-involving DME were included in the study, and they were administered topical nepafenac eye drops 0.1% thrice daily, for 6 months. Vision and foveal thickness were recorded at the baseline and 2nd, 4th, and 6th month follow-up visits. Results: The mean baseline and final LogMAR visual acuity were 0.35 and 0.18, respectively, and the mean baseline and final foveal thickness were 463.4 μm and 291.8 μm, respectively, both showing a statistically significant improvement (P < 0.05). Conclusion: Topical nepafenac is effective in the treatment of center-involving DME in this small case series; however, a large randomized study is warranted.